Phase 3CompletedAge-related condition
Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease
- Sponsor
- Technische Universität Dresden (Academic or other)
- Enrollment
- 132 planned
- Conditions
- Parkinson's Disease
- Interventions
- Coenzyme Q10 Nanodispersion (Nanoquinone); Placebo
- Ages
- adults, older adults
- Registry
- NCT00180037
Full record on ClinicalTrials.gov
From the registry
This study was designed to evaluate the symptomatic effects of Coenzyme Q10 nanodispersed solution in middle-stage Parkinson's disease (PD) patients (Hoehn\&Yahr II to III). The treatment phase includes three months period of 300 mg Coenzyme Q10 per day or placebo. The primary outcome measure was the combined Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III. The hypothesis of this study was that Coenzyme Q10 improves the energy status of the diseased dopaminergic neuronal cell type and thus producing more dopamine leading to an improvement of parkinsonian symptoms in PD patients.
Primary outcomes
- Unified Parkinson's Disease Rating Scale (UPDRS) Part II and III
History
Last registry update
Registered
Primary completion
Started